Skip to content

Dutch randomized trial comparing standard catheter-directed thrombolysis versus ultrasound-accelerated thrombolysis for thrombo-embolic infra-inguinal disease.

Dutch randomized trial comparing standard catheter-directed thrombolysis versus ultrasound-accelerated thrombolysis for thrombo-embolic infra-inguinal disease. - DUET study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON35325
Enrollment
60
Registered
2009-10-13
Start date
2009-11-30
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thrombo-embolic infra-inguinal arterial occlusion / thrombosed leg artery

Interventions

Group A (standard thrombolysis): During angiography a thrombolysis delivery catheter will be navigated proximally into the thrombus, followed by a control angiography at standardized intervals. Duri

Sponsors

Sint Antonius Ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Patients with recently (between 1 and 7 weeks) thrombosed femoro-popliteal or femoro-crural native arteries with ischemic complaints. 2. Patients with recently (between 1 and 7 weeks) thrombosed femoro-popliteal or femoro-crural venous or prosthetic bypass grafts with ischemic complaints. 3. Limb ischemia class I and IIa according to the Rutherford classification for acute ischemia. 4. Patients >18 years and

Exclusion criteria

Exclusion criteria: 1. Patients with isolated common femoral artery thrombosis including the origin of the superficial femoral artery and profunda femoral artery. 2. Patients with localized (7 weeks. 4. Patients with acute lower limb ischemia class IIb and III according to the Rutherford classification (see below). 5. Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated 6. Recent (110 mmHg, systolic blood pressure >200 mmHg) 9. Current malignancy 10. Patients with a history of prior life-threatening contrast medium reaction 11. Patients with uncorrected bleeding disorders (GI ulcera, mennorrhagia, liver failure) 12. Female patients with child bearing potential not taking adequate contraceptives or currently breastfeeding. 13. Pregnancy 14. Any patient considered to be hemodynamically unstable at onset of procedure 15. Patients refusing treatment. 16. Patients currently participating in another investigational drug or device study that have not completed the entire follow up period. 17. Patients 85 years old. 18. Severe co-morbid condition with life expectancy

Design outcomes

Primary

MeasureTime frame
1. Technical success defined as complete lysis of thrombus of the target vessel or bypass without distal thrombo-embolic complications. 2. Duration of catheter-derived thrombolysis needed for uninterrupted flow in the thrombosed native infra-inguinal artery or infra-inguinal bypass graft with outflow via at least one crural artery. 3. Number of units urokinasis needed for uninterrupted flow mentioned at point 1.

Secondary

MeasureTime frame
1. Thrombolysis induced hemorrhagic complications 2. 30-day mortality 3. Duration of hospital admission 4. Costs of hospital admission 5. 30-day patency of the target artery or bypass, as evidenced by Magnetic Resonance Angiography (MRA) 6. Drop of serum fibrinogen concentration to below 1.0 g/L during procedure 7. Conversion to open surgery 8. Distal thrombo-embolic complications

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)